These later studies indicate promise for the future development of PAD-based therapeutics for RA and for preserving lung function in patients with COPD, with the caveat of targeting extracellular PAD activity while preserving PAD antimicrobial activity within neutrophil phagosomes. Here, PADI4 is linked to rheumatoid arthritis.